User login
Key clinical point: Low lymphocyte-to-monocyte ratio (LMR) in patients with myelodysplastic syndrome (MDS) is associated with a favorable prognosis.
Major finding: LMR lesser than vs. greater than 5 was associated with a lower risk for leukemic transformation (median time not reached; P = .003) and better leukemia-free survival (median, 48 months vs. 21 months; P = .03).
Study details: Findings are from a retrospective study of 201 patients with a new diagnosis of MDS.
Disclosures: No source of funding was declared. The authors declared no potential conflicts of interest.
Source: Pénichoux J et al. Leuk Lymphoma. 2021 Apr 2. doi: 10.1080/10428194.2021.1907381
Key clinical point: Low lymphocyte-to-monocyte ratio (LMR) in patients with myelodysplastic syndrome (MDS) is associated with a favorable prognosis.
Major finding: LMR lesser than vs. greater than 5 was associated with a lower risk for leukemic transformation (median time not reached; P = .003) and better leukemia-free survival (median, 48 months vs. 21 months; P = .03).
Study details: Findings are from a retrospective study of 201 patients with a new diagnosis of MDS.
Disclosures: No source of funding was declared. The authors declared no potential conflicts of interest.
Source: Pénichoux J et al. Leuk Lymphoma. 2021 Apr 2. doi: 10.1080/10428194.2021.1907381
Key clinical point: Low lymphocyte-to-monocyte ratio (LMR) in patients with myelodysplastic syndrome (MDS) is associated with a favorable prognosis.
Major finding: LMR lesser than vs. greater than 5 was associated with a lower risk for leukemic transformation (median time not reached; P = .003) and better leukemia-free survival (median, 48 months vs. 21 months; P = .03).
Study details: Findings are from a retrospective study of 201 patients with a new diagnosis of MDS.
Disclosures: No source of funding was declared. The authors declared no potential conflicts of interest.
Source: Pénichoux J et al. Leuk Lymphoma. 2021 Apr 2. doi: 10.1080/10428194.2021.1907381